Prostate Cancer - Results from #160

French AFU Cancer Committee Guidelines - Update 2024-2026: Prostate cancer - Diagnosis and management of localised disease. November 26, 2024

French AFU Cancer Committee Guidelines - Update 2024-2026: Prostate cancer - Management of metastatic disease and castration resistance. November 26, 2024

Prioritizing precision: detection of prostate cancer using mri guided fusion needle biopsy across the pennsylvania urologic regional collaborative. November 26, 2024

Discrimination against Gay and Bisexual Patients in Prostate Cancer Treatment: Results from the Restore-2 Study. November 26, 2024

Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. November 26, 2024

Tumor architecture and emergence of strong genetic alterations are bottlenecks for clonal evolution in primary prostate cancer. November 25, 2024

Using a behaviour-change approach to support uptake of population genomic screening and management options for breast or prostate cancer. November 25, 2024

Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer. November 25, 2024

PSMA Radiotheranostics in Prostate Cancer: Principles, Practice, and Future Prospects. November 25, 2024

Organ-confined prostate cancer with negative surgical margins in an entirely-embedded radical prostatectomy is essentially non-lethal-a retrospective single-institutional study of 520 patients. November 25, 2024

Association of Race and Area of Deprivation Index with Prostate Cancer Incidence and Lethality. November 25, 2024

Central Nervous System Toxicity in Prostate Cancer Patients Treated with Androgen Receptor Signaling Inhibitors: A Systematic Review, Meta-analysis, and Network Meta-analysis. November 25, 2024

Cost-effectiveness analysis of additional local prostate radio therapy in metastatic prostate cancer from a medicare perspective. November 25, 2024

Dynamics in the Prostate Immune Microenvironment Induced by Androgen Deprivation Therapy. November 25, 2024

Integrated framework for quantitative T2-weighted MRI analysis following prostate cancer radiotherapy. November 22, 2024

Projected Outcomes of Reduced-Biopsy Management of Grade Group 1 Prostate Cancer: Implications for Relabeling. November 22, 2024

The Association of Where Patients with Prostate Cancer Live and Receive Care on Racial Treatment Inequities. November 22, 2024

Increased translation driven by non-canonical EZH2 creates a synthetic vulnerability in enzalutamide-resistant prostate cancer. November 22, 2024

Patients Can Administer Mobile Audio Recordings to Increase Knowledge in Advanced Prostate Cancer. November 22, 2024

Automated real-world data integration improves cancer outcome prediction. November 22, 2024

Page 9 of 1448